The Journal of Bone and Joint Surgery (American). 2006;88:72-75.
doi:10.2106/JBJS.E.01326
© 2006 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poole, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poole, A. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Biologic Markers and Disc Degeneration

A. Robin Poole, PhD, DSc

Corresponding author:
A. Robin Poole, PhD, DSc
Joint Diseases Laboratory, Shriners Hospitals for Children, 1529 Cedar Avenue, Montreal, Quebec H3G 1A6, Canada.
E-mail address: rpoole{at}shriners.mcgill.ca

In support of his research for or preparation of this manuscript, the author received grants or outside funding from the Shriners Hospitals for Children and the Canadian Arthritis Network. In addition, the author received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity (Dr. Poole is a consultant to IBEX Technologies). No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the author is affiliated or associated.

Biomarkers of skeletal turnover, such as the synthesis and degradation of extracellular matrix molecules in specific tissues, offer the opportunity to gain new insights into spinal pathology and treatment. The creation, use, and interpretation of these analytical body-fluid measures of process (rather than outcome) require a clear understanding of the nature of the molecules and events being measured. This review provides examples of how protein and carbohydrate assays of biomarkers can be used to measure the contribution from the intervertebral discs and vertebrae of the spine. With regard to spinal degeneration and ankylosing spondylitis, these investigations are providing important new information, in weeks rather than years, on the response of patients to treatment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?